Full history for every metric is available with a Kvantra account
Stock profile
Albany Molecular Research, Inc. (AMRI)
Current price
21.74 USD0.00%
Last close 31 Aug 2017Benchmarks
Key financial summary
Financials in USD| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 208 | 227 | 247 | 277 | 402 | 570 | 681 |
| Operating profit | $m | -19 | -21 | |||||
| Net profit | $m | -32 | -4 | 13 | -3 | -2 | -70 | -60 |
| EPS reported | $ | -1.65 | -1.48 | |||||
| Operating cashflow per share | $ | - | 0.63 | |||||
| Capex per share | $ | - | 1.21 | |||||
| FCF per share | $ | - | -0.58 | |||||
| Free cash flow | $m | -25 | -17 | |||||
| Net debt | $m | 566 | 585 | |||||
| Book value equity | $m | 299 | 317 | |||||
| Book value per share | $ | 7.04 | 7.47 | |||||
| Number of shares | m | 42.45 | 42.45 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.66 | 3.09 | |||||
| P/S LTM | x | 1.40 | 0.00 | |||||
| P/FCF LTM | x | -32.12 | 0.00 | |||||
| EV/EBITDA LTM | x | 37.16 | 15.45 | |||||
| EV/Sales LTM | x | - | 0.99 | |||||
| Earnings Yield LTM | % | - | -7.60% | |||||
| FCF Yield | % | -3.11% | - | |||||
| Quality | ||||||||
| ROE | % | - | -23.94% | |||||
| ROIC | % | - | -1.79% | |||||
| Operating margin | % | - | -3.29% | |||||
| Gross margin | % | - | 23.28% | |||||
| FCF/Sales | % | - | -4.35% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +41.78% | +48.85% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | - | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | - | 0.00% | |||||
| FCF/Debt | x | -0.04 | -0.03 | |||||
| Net Debt/EBITDA | x | - | 15.45 | |||||
| EBIT/Net interest | x | - | -0.47 | |||||
| Net debt/market cap | % | 71.12% | - | |||||
| Net debt/Equity | x | 1.89 | 1.85 | |||||
| Gross debt/equity | x | 2.07 | 1.98 | |||||
Company overview
No description available.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
AM
Albany Molecular Research, Inc. (AMRI)
AMRI · NASDAQ · Healthcare
21.74 USD0.00%
Benchmarks
Financialsin USD
20152016TTM
Total revenue $m402570681
Operating profit $m-19-21
Net profit $m-2-70-60
EPS reported $-1.65-1.48
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free